Back to search results

Stereotactic Body Radiotherapy for Localized Prostate Cancer

This study is looking at how well a treatment called TrueBeam Stereotactic Body Radiotherapy (SBRT) works for men with localized prostate cancer. SBRT uses focused, high-intensity radiation to target the tumor while trying to protect healthy tissues nearby. The study aims to see if this treatment helps patients and how it affects their quality of life over time. To join, you must be a man with prostate cancer that has been confirmed by a biopsy. The main goal is to see how many patients have their cancer controlled locally after five years. The current status of this study is unclear, and it plans to enroll 167 participants.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 167 men.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for five years to measure local control of the cancer.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04552509

TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer

Active, Not Recruiting
NAAll AgesInterventionalTreatment
Linda Chan, MD
~167 participants
Updated 2026-08-24 on ClinicalTrials.gov
What's tested:Stereotactic Body Radiotherapy

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Local control
Measured over 5 years

Conditions

Prostate Cancer

Explore related trials

Prostate Carcinoma

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Linda Chan, MD · PRINCIPAL_INVESTIGATOR · Memorial Health Services

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Biopsy within 12 months of date of registration required except for patients who already meet criteria for enrollment in the high risk arm of the protocol. For these patients, repeat biopsy will be at the discretion of the treating physician. In general, repeat biopsy is recommended for these patients, but is not required if it will not affect the treating physician's management decisions in regards to the care of the patient. 2. Clinical Stage I-IV, MX-M0 (AJCC 6th Edition)
M-stage determined by physical exam, CT, MRI, or Bone Scan. Bone scan not required for Monotherapy Risk Group patients unless clinical findings suggest possible osseous metastases. Bone Scan and contrast CT of the abdomen should be done patients in the Boost Risk Group patients. 3. Prostate volume: ≤ 100 cc (recommended not required)
Determined using: volume = π/6 x length x height x width
Measurement from CT or ultrasound ≤90 days prior to registration. 4. ECOG performance status 0-1 5. Completion of patient questionnaires in section 4.7. 6. Consent signed

What this trial measures

  • Local control5 years

    Rate of disease recurrence locally